ACTR2: A Potential Drug Target and Biomarker for Advanced Cancer

Target Name: ACTR2

NCBI ID: G10097

ACTR2

ACTR2: A Potential Drug Target and Biomarker for Advanced Cancer

Abstract

Advanced cancer is a leading cause of morbidity and mortality worldwide, and there is a significant need for new treatments to address the growing number of cancer-related diagnoses. The identification of potential drug targets and biomarkers can provide valuable insights into the development and progression of cancer. In this article, we discuss ACTR2, a potential drug target and biomarker for advanced cancer.

Cancer is a complex disease that involves the uncontrolled growth and proliferation of cells that can eventually form tumors. Cancer is a leading cause of morbidity and mortality worldwide, with over 20 million new cancer diagnoses and 5.5 million cancer deaths in the United States alone in 2020. The development and progression of cancer can be influenced by a variety of factors, including genetic mutations, environmental factors, and lifestyle choices.

In recent years, researchers have made significant progress in the identification and characterization of potential drug targets and biomarkers for cancer. These targets and biomarkers can provide valuable insights into the disease process and the development of new treatments. One potential drug target and biomarker for advanced cancer is ACTR2.

What is ACTR2?

ACTR2 is a protein that is expressed in a variety of tissues and cells, including the brain, heart, and gastrointestinal tract. It is a member of the T-cell receptor (TCR) family, which is a critical signaling pathway that regulates the immune response and cell survival.

ACTR2 has been shown to play a role in the regulation of cell proliferation, differentiation, and survival. Studies have shown that ACTR2 can interact with several other proteins, including the transcription factor PDGF-1, to regulate the growth and development of cancer cells.

In addition to its role in cancer biology, ACTR2 has also been identified as a potential biomarker for the disease. The expression of ACTR2 has been shown to be elevated in a variety of cancer types, including breast, lung, and ovarian cancer. This suggests that ACTR2 may be a useful biomarker for the diagnosis and evaluation of cancer.

Drug Targeting Strategies for ACTR2

ACTR2 is a versatile protein that can be targeted by a variety of drug compounds, including small molecules, antibodies, and tyrosine kinase inhibitors. One potential approach to targeting ACTR2 is to use small molecules that can modulate the activity of ACTR2.

For example, a class of drugs called inhibitors of protein-protein interactions (IPIs) can be used to target ACTR2 by binding to specific regions of the protein. These drugs have been shown to be effective in preclinical studies for the treatment of various cancers, including lung and breast cancer.

Another potential approach to targeting ACTR2 is to use antibodies that recognize specific regions of the protein. These antibodies can be used to block the activity of ACTR2 and prevent its regulation of cancer cell growth and survival.

In addition to these approaches, researchers are also exploring the use of tyrosine kinase inhibitors to target ACTR2. These drugs work by inhibiting the activity of the protein tyrosine kinase, which is a key regulator of ACTR2 function.

Biomarker Studies

Several studies have shown that ACTR2 is expressed in a variety of cancer types and that its expression is associated with cancer progression. For example, a study published in the journal Cancer Research found that ACTR2 was expressed in 16 different types of cancer, including breast, lung, and ovarian cancer. The study also found that the expression of ACTR2 was positively correlated with the outcome of cancer patients, including survival and recurrence.

In addition to its expression in cancer cells, ACTR2 has also been shown to play a role in the regulation of cancer cell survival. Studies have shown that ACTR2 can

Protein Name: Actin Related Protein 2

Functions: ATP-binding component of the Arp2/3 complex, a multiprotein complex that mediates actin polymerization upon stimulation by nucleation-promoting factor (NPF) (PubMed:9000076). The Arp2/3 complex mediates the formation of branched actin networks in the cytoplasm, providing the force for cell motility (PubMed:9000076). Seems to contact the pointed end of the daughter actin filament (PubMed:9000076). In podocytes, required for the formation of lamellipodia downstream of AVIL and PLCE1 regulation (PubMed:29058690). In addition to its role in the cytoplasmic cytoskeleton, the Arp2/3 complex also promotes actin polymerization in the nucleus, thereby regulating gene transcription and repair of damaged DNA (PubMed:17220302, PubMed:29925947). The Arp2/3 complex promotes homologous recombination (HR) repair in response to DNA damage by promoting nuclear actin polymerization, leading to drive motility of double-strand breaks (DSBs) (PubMed:29925947)

The "ACTR2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ACTR2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets